Stada · PTH1R · Recombinant Proteins
teriparatide is a recombinant proteins developed by Stada. It is approved for therapeutic indications via injectable (others).
| Brand Names | Movymia |
| Company | Stada |
| Drug Class | Recombinant Proteins |
| Molecular Target | PTH1R |
| Route | Injectable (Others) |
| Status | Approved |
teriparatide acts on 1 molecular target:
| PTH1R | parathyroid hormone 1 receptor (PTHR, EKNS) |
teriparatide is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Musculoskeletal and connective tissue disorders | Osteoporosis | ✓ Approved |
Lynch Lauren K LK, Shane Elizabeth E, Cohen Adi A
Kang Hyun Tak HT, Jin Woong Geun WG, Kang Hong Je HJ
Stress fractures of the forearm are uncommon, and to our knowledge, sequential involvement of both the ulna and radius has not been well characterized. Neurofibromatosis type 1 is associated with increased bone fragility and delayed fracture healing due to impaired osteoblastic differentiation, reduced mineralization capacity, and increased osteoclastic activity. We report the case of a woman in her early 60s with neurofibromatosis type 1 and lower-extremity weakness who relied on upper-extremity weight-bearing ambulation. She initially developed a nondisplaced transverse stress fracture of the proximal ulnar shaft with delayed union, which subsequently achieved union following conservative treatment, including teriparatide. Approximately 24 months after the initial ulnar fracture, she developed a new nondisplaced stress fracture of the radial shaft, suggestive of a possible stress-transfer phenomenon related to altered load distribution across the forearm. Repeated conservative treatment with strict weight-bearing restriction resulted in radiographic union with restoration of functional forearm motion. This case highlights the importance of recognizing altered forearm load distribution to reduce the risk of secondary stress injury.
Liévano Ana Karina Sarmiento AKS, Sarmiento Hannah Vanessa Ceballos HVC, Vega Nicolás Jiménez NJ, Avila Yeisson Alejandro Arias YAA et al.
Medication-related osteonecrosis of the jaw (MRONJ) is a challenging complication associated with antiresorptive and antiangiogenic therapies. Prolonged suppression of bone remodeling has been implicated as a key mechanism in its pathophysiology. Teriparatide, an osteoanabolic agent that restores coupled bone remodeling, has been proposed as a potential therapeutic strategy. This review aimed to synthesize reported clinical outcomes of teriparatide use in MRONJ within a systemic remodeling-based framework. We conducted a structured descriptive review based on a systematic literature search and reported in accordance with PRISMA 2020. Studies reporting therapeutic use of teriparatide in established MRONJ were included regardless of the triggering medication. Data were extracted on patient characteristics, MRONJ stage, lesion site, antiresorptive exposure, teriparatide regimen, antiresorptive interruption, antiresorptive type, and clinical outcomes. Because of substantial heterogeneity in study design, patient populations, co-interventions, and outcome reporting, evidence was synthesized qualitatively. Thirty-four publications including 207 patients were included. Clinical outcomes were available for 201 patients: complete coverage/healing was reported in 163, partial improvement in 24, no change in 12, and worsening in 2. Teriparatide discontinuation or dropout after treatment initiation was reported in 13 patients. Stage 2 disease predominated among stageable cases, mandibular involvement was the most frequent anatomical site, and daily teriparatide dosing was more commonly reported than weekly regimens. Bisphosphonate exposure predominated, whereas denosumab-associated cases were fewer; therefore, differential effectiveness by antiresorptive class could not be determined. Published reports describe frequent clinical improvement after teriparatide use in MRONJ. However, the evidence remains descriptive, heterogeneous, and commonly confounded by concomitant therapies. These findings support a biologically plausible remodeling-based interpretation but do not establish efficacy or define teriparatide as standard therapy.
Maayan Omri O, Khattab Mahmood M, Song Junho J, Alasadi Yazan Y et al.
Systematic review and meta-analysis. To determine whether perioperative anabolic osteoporosis pharmacotherapy is associated with lower rates of (1) proximal junctional kyphosis (PJK) and (2) reoperation for mechanical failure following adult spinal deformity surgery. Mechanical complications occur in 15 to 40 percent of patients following adult spinal deformity surgery. Although poor bone quality has been associated with mechanical failure, no quantitative synthesis has tested whether perioperative pharmacotherapy alters these outcomes. PubMed, Embase, Scopus, and Cochrane CENTRAL were searched through April 30, 2026 (PROSPERO CRD420261374961). Random-effects meta-analysis was performed for the primary and prespecified secondary outcomes. The primary pool comprised anabolic-exposed studies; a class-agnostic pool that additionally included a single antiresorptive-dominant, claims-based study was retained as a sensitivity analysis. Thirteen studies (one randomized controlled trial, twelve observational; 2,247 patients) met inclusion criteria. Teriparatide was the primary or sole study agent in nine of thirteen studies. Anabolic pharmacotherapy was associated with reduced odds of PJK (pooled OR 0.51, 95% CI 0.30 to 0.86, P=0.012; I2=0%, k=5) and of reoperation for mechanical failure (OR 0.36, 95% CI 0.14 to 0.88, P=0.025; I2=55%, k=4). A broadened-class sensitivity analysis including the antiresorptive-dominant study was directionally consistent (OR 0.63, 95% CI 0.42 to 0.94, P=0.024). Leave-one-out sensitivity analysis preserved the direction of the PJK effect across all iterations. Perioperative anabolic osteoporosis pharmacotherapy is associated with lower rates of proximal junctional kyphosis and reoperation following adult spinal deformity surgery, providing the first pooled evidence that the underlying bone-quality substrate may be pharmacologically modifiable. The certainty of this evidence is low; these findings support incorporating bone health optimization into perioperative planning as a modifiable target and prioritizing randomized trials of specific agents. IILevel of Evidence: II: Systematic review of cohort studies with one randomized controlled trial.
Lim Dong-Ju DJ, Kang Min Kue MK
Systematic review using Synthesis Without Meta-analysis (SWiM). To synthesize evidence on osteoporosis and mechanical outcomes after fusion for degenerative lumbar scoliosis (DLS) and related adult spinal deformity (ASD), and appraise perioperative teriparatide or romosozumab. DLS-specific long-fusion evidence is sparse; much literature comprises related ASD or indirect short-segment/mixed-fusion cohorts. PubMed, Embase, CENTRAL, and Web of Science were searched through January 31, 2026, with a focused PubMed verification audit during revision. PROSPERO registration on April 22, 2026 followed the search; post-registration eligibility and analysis deviations are disclosed. Core DLS evidence required explicit long-segment fusion or ≥4 fused/instrumented levels; a stricter ≥5-vertebrae subset was examined. Adjusted estimates were reported per study without pooling. Risk of bias used QUIPS, RoB 2, or ROBINS-I; certainty used GRADE. Twenty-one index primary reports informed the synthesis; eight were core DLS long-fusion reports; one overlapping companion was linked to its index cohort. Of eight core reports, five showed adverse adjusted associations, one was adjusted-null, and two were mixed across bone measures. The strict ≥5-vertebrae subset contained three adverse reports. Direct estimates included osteoporosis OR 8.19 (95% CI, 2.40-27.97) for screw loosening, S1 VBQ OR 4.565 (1.430-14.568) for PJK, osteoporosis OR 6.713 (1.667-27.031) for mechanical complications, and lumbosacral HU OR 0.941 (0.906-0.977) for distal instrumentation problems. Two reports had internally inconsistent regression tables; unsafe numeric effects were not extracted. Cohort overlap, heterogeneous measures/endpoints, and indirect evidence precluded pooling; three anabolic studies did not establish a DLS-specific class effect. Most core DLS reports linked lower bone quality to mechanical complications, but retrospective design, probable cohort overlap, measure-dependent null findings, and reporting defects make certainty very low. No pooled DLS-specific magnitude is justified. Effects on final alignment and disability remain unresolved, and perioperative anabolic therapy is promising but not definitive. 3.
Song Yeqiong Y, Zhang Ruixing R, Zhang Xinyue X, Wang Jingkai J et al.
Bone metabolism-related disorders represent a significant global health burden, due to their high prevalence and substantial socioeconomic costs, particularly osteoporosis. Conventional antiresorptive and anabolic agents have well-established clinical utility, such as bisphosphonates, denosumab, teriparatide, and romosozumab. Nevertheless, their long-term clinical use remains limited by safety concerns and inadequate efficacy in a subset of patients. In this review, we highlight recent chemical innovations designed to mechanistically reprogram the skeletal microenvironment and overcome those longstanding barriers. We also analyze how the metabolic coupling signals govern bone bioenergetics, particularly within the Wnt and RANKL axes. We place specific focus on three emerging and transformative strategies: proteolysis-targeting chimeras (PROTACs), bone-targeted senolytics, and direct metabolic modulators. Ultimately, we provide a multidisciplinary roadmap for the development of next-generation therapeutics to achieve durable skeletal restoration in patients with bone metabolic disorders.
+2886 more articles available with a free account
Sign up free to view all articles →